Video

Eran Orr: The Need For Better ADHD Screening

Author(s):

Screenings for ADHD have not improved in several years.

While treatment for attention deficit/hyperactivity disorder (ADHD) have improved over time, diagnostics generally have not.

For the last several decades, screenings and diagnostics for ADHD has been done through questionnaires for the patient, as well as for teachers and parents of patients.

There remains a need to improve that.

In an interview with HCPLive®, Evan Orr, Founder and CEO of XRHealth, said he is hopeful that new technology could be used to better screen patients for ADHD.

XRHealth recently unveiled a new ADHD virtual reality platform with the goal of improving well-known ADHD cognitive functioning, including attention, impulsivity, and higher and more complex thinking functions such as initiating, organizing, planning, and fully executing daily tasks.

Orr said the VR tools could be a real boost for ADHD patients, particularly during the coronavirus disease 2019 (COVID-19) pandemic.

The new tool will allow doctors to create virtual worlds where the patient must complete a task while avoiding distractions.

The new system is based on the brain’s ability to restructure itself in attempt to overcome existing challenges, referred to as the brain’s plasticity principle.

Related Videos
Christian Sadaka, MD: Significant Increase in Pediatric Gastroparesis Hospital Admissions After COVID-19
Akif Shameem, MD: Generalized Anxiety Disorder Linked to Longer Hospitals in Children with IBD
Jonathan Meyer, MD: Cognitive Gains, Dopamine-Free Schizophrenia Treatment with Xanomeline Trospium Chloride
Chelsie Monroe: Challenges Clinicians Should Consider When Prescribing Muscarinic Modulators for Schizophrenia
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
© 2024 MJH Life Sciences

All rights reserved.